Clinical Trial Update: Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

View source ↗

Summary

Pfizer's expanded access protocol for crizotinib in ROS1-rearranged non-small cell lung cancer is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Carcinoma, Non-Small-Cell Lung | Status: NO_LONGER_AVAILABLE